test directorySearch Results
Click here to search again.
Test Name:
CA 19-9, by Chemiluminescence, Serum
- SBMF No:
30199 - Performance Lab Name:
Manual Lab - Test Mnemonic:
CA 19-9 - ABN:
May be required – Medical Necessity - CPT Code:
86301 - LOINC Code:
24108-3 - Also Known As:
Pancreatic Cancer Tumor Marker
Gastro-Intestinal Cancer Marker
Tumor Marker - Spec Type:
Serum - Spec Container:
Gold top (SST) or red top (serum) tube - Pref Vol:
0.5 mL - Min Vol:
0.3 mL - Fasting:
No - Spec Collect:
Routine venipuncture - Spec Process:
Clot 30 minutes
Promptly centrifuge 15 minutes
If sample not sent to SBMF on day collected:
– Immediately transfer serum to separate plastic tube
– Freeze and transport frozen - Spec Store Transport:
Refrigerated (48 hours) or frozen - Spec Stability:
8 hours room temperature (20-30°C)
48 hours refrigerated (2-8°C)
Greater than 48 hours, freeze (-20°C) – Do not use frost-free units that undergo repeated freeze/thaw cycles - Methodology:
Chemiluminescent Immunoassay (CLIA) - Use:
Aid in monitoring disease status in patients with confirmed pancreatic cancer
Note: SBMF provides serial reporting for this test at no additional charge - Clinical Significance:
CA 19-9 is a tumor-associated antigen that is reactive with an antibody that was produced in response to immunization with a human colon cancer cell-line. Although the antibody was derived from a colon cancer cell-line, studies have found assays for CA 19-9 more useful in the diagnosis and management of patients with pancreatic cancer than colon neoplasia. CA 19-9 has also been shown to be a more sensitive and specific marker of pancreatic cancer than other serologic markers.
Very little of the CA 19-9 antigen is found in the blood of normal patients or those with benign disorders, but most patients with pancreatic cancer have elevated levels of CA 19-9. Many published studies have shown that patients on various therapeutic regimens with clinically stable or responsive disease had stable or decreasing serum CA 19-9 levels, whereas patients with progressive disease had rising serum levels of CA 19-9.
The clinical management of pancreatic cancer is extremely difficult with most pancreatic cancers having metastasized by the time of diagnosis. Treatment consists of surgical intervention, radiation therapy, chemotherapy and palliative care measures as well as nutritional management. Monitoring the progression of disease is critical in the management of this disease. Therefore, the serial monitoring of CA 19-9 levels as an adjunct to imaging and clinical assessment is valuable in the management of pancreatic cancer patients.
- Reference Range:
Less than 35 U/mL - Day Run:
Tue, Thu, Sat - Time Run:
8:00 am - Time Reported:
5:00 pm - Test Type:
TUMOR MARKER
